We are live on ! Find out more
LABP

Landos Biopharma, Inc. Common Stock
LABP

Delisted

LABP was delisted on the 23rd of May, 2024.

Back to rankings

40 hedge funds and large institutions have $120M invested in Landos Biopharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

71% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 7

14% more funds holding

Funds holding: 35 → 40 (+5)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

64% less capital invested

Capital invested by funds: $331M → $120M (-$211M)

Holders
40
Holders Change
+5
Holders Change %
+14.29%
% of All Funds
0.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
12
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$2.49M
2
Renaissance Technologies
Renaissance Technologies
New York
+$1.68M
3
Morgan Stanley
Morgan Stanley
New York
+$1.6M
4
Walleye Capital
Walleye Capital
New York
+$1.11M
5
Two Sigma Investments
Two Sigma Investments
New York
+$576K

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$3.11M
2
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$1.82M
3
LGM
Logos Global Management
California
-$315K
4
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
-$275K
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$265K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$71.4M – – –
RI
2
RTW Investments
New York
$20.5M – – –
OMC
3
OUP Management Company
Pennsylvania
$8.77M +$19.2M +182,748 New
LGM
4
Logos Global Management
California
$6.6M -$315K -3,000 -2%
BlackRock
5
BlackRock
New York
$2.26M +$2.49M +23,681 +101%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.46M +$105 +1 +0%
JP Morgan Chase
7
JP Morgan Chase
New York
$1.44M -$109K -1,037 -3%
O
8
OrbiMed
New York
$1.36M – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$821K +$1.68M +16,020 +1,470%
Morgan Stanley
10
Morgan Stanley
New York
$738K +$1.6M +15,204 +8,738%
Macquarie Group
11
Macquarie Group
Australia
$706K – – –
AI
12
ArchPoint Investors
Florida
$618K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$546K +$10.4K +99 +0.9%
State Street
14
State Street
Massachusetts
$516K +$315 +3 +0%
Walleye Capital
15
Walleye Capital
New York
$505K +$1.11M +10,521 New
Two Sigma Investments
16
Two Sigma Investments
New York
$263K +$576K +5,478 New
Northern Trust
17
Northern Trust
Illinois
$221K -$7.04K -67 -1%
Walleye Trading
18
Walleye Trading
New York
$208K +$455K +4,328 New
Bank of America
19
Bank of America
North Carolina
$150K +$313K +2,974 +1,996%
Two Sigma Advisers
20
Two Sigma Advisers
New York
$123K +$270K +2,570 New
Goldman Sachs
21
Goldman Sachs
New York
$84K +$185K +1,757 New
JF
22
Jump Financial
Illinois
$73K +$160K +1,520 New
Charles Schwab
23
Charles Schwab
California
$68K – – –
Bank of New York Mellon
24
Bank of New York Mellon
New York
$63K -$20.7K -197 -13%
SO
25
STRS Ohio
Ohio
$54K – – –
1
2

LABP Hedge Fund Activity: Q4 2021 in Review

40 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q4 2021, worth a combined $120M — down 64% from $331M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new LABP positions and 6 closed out — a net gain of 5 holders — while 12 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $2.49M. The largest seller was Woodline Partners, exiting entirely with an estimated $3.11M sold.

  • 40 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q4 2021, up from 35 in Q3 2021.
  • Funds reported $120M of Landos Biopharma, Inc. Common Stock stock for Q4 2021, down 64% quarter-over-quarter.
  • 11 funds opened new Landos Biopharma, Inc. Common Stock positions in Q4 2021 and 6 closed out, a net change of +5 holders.
  • The largest Landos Biopharma, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $2.49M added.
  • The largest Landos Biopharma, Inc. Common Stock seller in Q4 2021 was Woodline Partners, an estimated $3.11M sold.

Based on aggregated 13F filings for Q4 2021.